Q1

amino acid sequence chimeric complexes that have superior pharmacological properties than the uncombined drugs. The chimeric complexes are designed to target only desired organs, without affecting other organs where the drug's activity is not desired, and to enhance drug bioavailability without losing the drugs' therapeutic properties.--

REMARKS

An abstract of the technical disclosure had not been filed at the time the application was filed with the USPTO. Applicant respectfully requests that the abstract above be included as part of the specification of the above-identified application.

Respectfully submitted

BY James 26 La

McDermott, Will & Emery

James E. Eakin

Reg. No.: 27,874

(650)233-5500